Drug Trial Radar · NCT07908446
Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the effectiveness and safety of switching to bictegravir/lenacapavir (BIC/LEN) fixed-dose combination (FDC) compared with continuing stable baseline regimens (SBR) in virologically suppressed people with HIV. The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) fixed-dose combination (FDC) tablets versus continuing their stable baseline regimen (SBR) in virologically suppressed people with HIV.
Conditions
- HIV-1 Infection
Interventions
BIC/LEN FDCDrug
Tablet administered orally
LenacapavirDrug
Tablet administered orally
SBRDrug
SBR will include approved ARTs like: integrase strand-transfer inhibitor (INSTI) + 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs), excluding bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), boosted-protease inhibitor (PI) + 2 NRTIs, nonnucleoside reverse transcriptase inhibitor (NNRTI) + 2 NRTIs, or dolutegravir (DTG)/rilpivirine (RPV) or cabotegravir (CAB) + RPV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants With HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 24, as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmTime frame: Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.